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Abstract The mechanisms by which epidermal growth factor 
(EGF) enhances the production of pro-matrix metalloproteinase 
3 (proMMP-3/prostromelysin 1) and tissue inhibitor of metallo- 
proteinases (TIMP)-I were investigated using human uterine 
cervical fibroblasts. The treatment of the cells with EGF for 24 h 
resulted in about 5-6-fold increase in the production of 
proMMP-3 and TIMP-1 compared with the untreated control 
cells. This increase was accompanied by an increase of 
proMMP-3 and TIMP-1 mRNAs. However, an about 3- and 
2-fold increase in the production of proMMP-3 and TIMP-1, 
respectively, was observed as early as 1 h after the treatment of 
the cells with EGF, and it was not accompanied by any apparent 
increase in proMMP-3 and TIMP-1 mRNAs. This early effect 
of EGF on the enhanced production of proMMP-3 and TIMP-1 
was not inhibited by actinomycin D, even though actinomycin D 
inhibited the synthesis of the total RNA in both the EGF-treated 
and untreated cells. These results indicate that EGF enhances the 
apparent production of proMMP-3 and TIMP-I  by two 
mechanisms: one by the accelerated translation of their mRNAs; 
and the other by the enhanced transcription of their genes. The 
former event takes place much earlier than the latter. 
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1. Introduction 
Matrix metalloproteinases (MMPs) are considered to play 
an important role in the degradation of connective tissue ma- 
trix components in both physiological nd pathological proc- 
esses such as in wound healing, embryogenesis, angiogenesis, 
rheumatoid arthritis, tumor cell invasion and metastasis [1,2]. 
It is well-recognized that a number of cytokines and growth 
factors, e.g. IL-1, TNFcx, transforming growth factor ~ and 
EGF, participate in the regulation of production of MMPs 
*Corresponding author. Fax: (81) (426) 76-5734. 
Abbreviations: EGF, epidermal growth factor; hEGF, 21-1eu recom- 
binant human-like EGF; IL-1, interleukin 1; TNF~, tumor necrosis 
factor c~; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor of 
metalloproteinases-l; TPA, 12-o-tetradecanoyl-phorbol-13-acetate; 
TRE, TPA-responsive element; AP-1, activator protein-l; FBS, fetal 
bovine serum; MEM, Eagle's minimum essential medium; PBS, 
phosphate buffer saline; LAH, lactalbumin hydrolysate; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; SDS-PAGE, sodium 
dodecyl sulfate-polyacrylamide gel lectrophoresis. 
and their inhibitors (TIMPs) in connective tissue cells [3-6], 
and the overall imbalance between MMPs and TIMPs is likely 
to be a key determinant of connective tissue matrix catabolism 
under physiological nd pathological conditions [7]. All these 
cytokines and growth factors regulate the transcription of a 
number of MMP genes (see [1] for a review). For example, 
EGF augments he production of proMMP-1 (interstitial pro- 
collagenase), proMMP-3 (prostromelysin 1) and TIMP-1 [8] 
along with an increase of their mRNAs [8-10]. McDonnell et 
al. [11] have reported that the EGF-induced gene expression 
of proMMP-3 requires activation of protein kinase C and 
induction of proto-oncogenes, c-fos and c-jun. The induced 
c-Fos and c-Jun proteins form a Fos-Jun heterodimer which 
initiates the transcription of the proMMP-3 gene through the 
its binding to TRE/AP-l-binding site [12 14]. Similarly, the 
induction of proMMP-1 and proMMP-3 transcripts by phor- 
bol myristate acetate [15], IL-1 [16], and TNFc~ [17] is thought 
to be in part mediated by AP-1. However, an increase of 
proMMP-3 transcripts requires several hours after treating 
with EGF or with other stimuli [11]. 
In this report, we have investigated the production of 
proMMP-3 and TIMP-1 at much earlier time points (within 
1 h) after EGF treatment using human uterine cervical fibro- 
blasts, and observed that the synthesis of these gene products 
was enhanced well before an increase of their mRNAs was 
detected. Our studies uggest that the initial augmentation in 
proMMP-3 and TIMP-1 production by EGF results from 
accelerated translation of their mRNAs. 
2. Materials and methods 
2.1. Materials 
The following reagents were obtained commercially: MEM was 
from Grand Island Biochemical, Grand Island, NY. FBS was from 
Whittaker, Walkersville, MD. Actinomycin D-mannitol was from Sig- 
ma, St Louis, MO. Horseradish peroxidase-conjugated donkey anti- 
(sheep IgG-(H+L))IgG was from The Binding Site, Birmingham, UK. 
The ECL-Western blotting detection reagents were from Amersham, 
Tokyo, Japan. hEGF was from PROGEN Biotechnik, Heidelberg, 
Germany. [5-aH]uridine was from American Radiolabeled Chemicals, 
St Louis, MO. Sheep anti-(human MMP-3) antibody and sheep anti- 
(human TIMP-1) antibody were prepared as described previously 
[18,19]. A 1.4-kb cDNA clone encoding human MMP-3 was isolated 
from the ~gtll cDNA library of human rheumatoid synoviocytes. 
The cDNA sequence was confirmed by the dideoxy chain termination 
method. TIMP-1 cDNA (0.7 kb) was kindly provided by Dr. M. 
Naruto at Basic Research Laboratories, Toray Industries, Kamakura, 
Kanagawa, Japan. GAPDH cDNA (1.1 kb) was from CLONTECH 
Laboratories, Palo Alto, CA. Other reagents used were the same as in 
the previous paper [20]. 
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2.2. Cell culture 
Preparation and maintenance of human uterine cervical fibroblasts 
were the same as described previously [20]. For most experiments, the 
cells up to the 10th passage in a 12-well plate were used. After con- 
fluence, the cells were cultured without serum for 24 h and then 
treated with hEGF in the serum-free MEM/0.2% (w/v) LAH to stim- 
ulate the production of proMMP-3 and TIMP-1. All experiments 
were conducted at least in duplicate. 
2.3. ECL-Western blotting for proMMP-3 and TIMP-1 
ProMMP-3 and TIMP-1 in the culture media were analyzed by 
Western blotting. Each sample from triplicate wells was concentrated 
by precipitating the proteins with final 3.3% (w/v) trichloroacetic a id 
and then subjected to SDS PAGE with 11.5% (w/v) acrylamide gel 
under reducing conditions [21]. After electrophoresis, proteins in the 
gel were electrotransferred onto a nitrocellulose filter. The filter was 
reacted with sheep anti-(human MMP-3) or sheep anti-(human 
TIMP-1) antibody, which was then complexed with the horseradish 
peroxidase-conjugated donkey anti-(sheep IgG(H + L))IgG. Immuno- 
reactive proMMP-3 and TIMP-1 were indirectly visualized using the 
ECL-Western blotting detection reagents according to the manufac- 
turer's instructions. The amounts of immunoreactive antigens were 
determined by densitometric analysis. 
2.4. Extraction of RNA, slot-blot analys& and Northern blott&g 
Total cytoplasmic RNA of cultured human uterine cervical cells 
was isolated using a commercial RNA extraction kit (Isogen; Nippon 
Gene, Toyama, Japan) according to the manufacturer's instructions. 
Total RNA was denatured with formaldehyde and then transferred 
onto a nylon membrane. Slot-blot analysis was carried out by the 
method of Wahl [22]. Membrane was hybridized with 32p-labeled 
nick-translated proMMP-3, TIMP-1 and [3-actin cDNAs at 42°C in 
10×Denhardt's solution, 5×SSPE (I×SSPE is 0.18 M NaC1/0.01 M 
NaH2POjI.1 mM disodium EDTA) containing 0.1% (w/v) SDS, and 
150 lag of heat-denatured salmon sperm DNA/ml. After hybridization, 
the membrane was washed twice in I×SSC (0.15 M NaC1/0.015 M 
sodium citrate, pH 7.0)10.1% (w/v) SDS, and then washed in 
0.1 ×SSC/0.1% (w/v) SDS at room temperature for 30 rain. The radio- 
activity was measured using Bio-imaging analyzer BAS 2000 (Fuji 
Photo Film, Tokyo, Japan). 
Northern blotting was also carried out as follows. Each total RNA 
which was denatured with formaldehyde and formamide, was run on 
formaldehyde-agarose gels and then transferred onto a nylon mem- 
brane. Membrane was hybridized with 32P-labeled random primed 
proMMP-3, TIMP-1 and GAPDH cDNAs at 42°C in a solution 
containing 5×SSC, 1 ×Denhardt's solution, 50 mM sodium phosphate 
(pH 6.5), 0.1% (w/v) SDS, 50% formamide and 200/ag of heat-dena- 
tured salmon sperm DNA/ml. After hybridization, the membrane was 
washed for 10 min at room temperature in 2×SSC/0.1% (w/v) SDS 
and exposed to Konica X-ray film/medical at -80°C. 
2.5. Measurement of the synthesis of total RNA 
Confluent human uterine cervical cells in 12-well plates were de- 
prived from serum for 24 h, and then incubated with [5-:~H]uridine (37 
kBq/ml) in MEM/0.2% (w/v) LAH under presence or absence of 
hEGF (100 ng/ml). After pulse-labeling for 1 h, the culture media 
were removed from the 12-well plates. The cells were washed twice 
with calcium and magnesium-free PBS, and treated with ice-cold 10% 
(w/v) trichloroacetic acid for 30 min. The cells were solubilized with 
0.5 N NaOH, and the radioactivity in the solution was then measured. 
3. Results and discussion 
EGF regulates various cellular events in many cell types. 
For  example, augmentat ion of the product ion of p roMMPs  
and TIMP-1 in human and rat fibroblasts is closely correlated 
to connective tissue matrix remodeling [8 11]. We investigated 
the mechanisms by which EGF enhanced the product ion of 
p roMMP-3  and TIMP-1 using human uterine cervical fibro- 
blasts. 
When human uterine cervical fibroblasts were treated with 
hEGF for 24 h, the accumulat ion of proMMP-3  and T |MP- I  
in the culture media increased in a dose-dependent manner  (1- 
100 ng/ml) (data not shown) as reported for MRC-5 human 
fibroblasts [10]. We then examined the time course of 
p roMMP-3  and TIMP-1 product ion after the treatment of 
the cells with hEGF at a concentrat ion of 100 ng/ml. As 
shown in Fig. 1, there was an about 2-3-fold increase in the 
product ion of both components as early as 1 h after hEGF 
treatment when compared with the untreated control cells 
(panel A), and it cont inued up to 24 h (panel B). An enhance- 
ment of specific protein synthesis in response to cytokines or 
growth factors is usually paralleled with an increase in 
mRNA;  this applies to the regulation of proMMP-3 and 
TIMP-1 in many cell types [1,23]. We, therefore, examined 
the levels of proMMP-3 and TIMP-1 mRNAs  after treating 
the cells with hEGF (100 ng/ml), but an increase of these 
mRNAs  was first detected at 6 h and reach to a steady-state 
level after 8 h (Fig. 2). In a separate experiment, we also 
observed that an increase in incorporat ion of [3H]uridine 
into the total RNA was first detected at 6 h after hEGF 
treatment (data not shown). Fig. 3 compares the time-depend- 
ent increase of proMMP-3  and TIMP-1 protein production 
and their mRNA levels. It is noteworthy that there was a 2-3- 
fold increase in the product ion of both proMMP-3 and 
TIMP-1 in the hEGF-t reated cells at 1-, 2- and 4-h time 
points when compared with the control cells, but there was 
no detectable increase in their mRNAs.  The levels of 
proMMP-3  and TIMP-1 proteins produced by the hEGF-  
treated cells after 12 h and 24 h were 3-4- and 5-6-fold higher 
than those of the control cells, respectively, where their 
mRNA levels increased only 1.7-1.9-fold (Fig. 3). These ob- 
servations uggest hat the increase of Prommp-3 and TIMP-1 
product ion during the first 4 h of EGF  treatment was due to 
the enhanced translation of their preexisting mRNAs  at a low 
level and the latter product ion (after 6 h) were reflected from 
[A] 
hEGF (100ng/ml)  - + - + 
proMMP-3  --~ 
TIMP-1 - * ~  
I I1__ ]  
l h  2h 
[B] 
proMMP-3  ~ 
TIMP-1 -*  
T ime(h)  1 2 4 6 8 12 24 2 4 6 12 24 
T II J 
hEGIF (100ng/ml)  NONE 
Fig. 1. Time-dependent effects of EGF on the production of 
proMMP-3 and TIMP-1 in human uterine cervical fibroblasts. Con- 
fluent uterine cervical fibroblasts at the 5th passage in 12-well plates 
were deprived from serum for 24 h prior to the stimulation with or 
without hEGF (100 ng/ml) in 0.2% (w/v) LAH/MEM. At the times 
indicated, culture media (3 ml for panel A; 1 ml for panel B) were 
harvested and the proteins precipitated by mixing with 1/5 vol. of 
20% (w/v) trichloroacetic acid. The precipitates collected by centrifu- 
gation were dissolved in reducing SDS-PAGE sample buffer and 
subjected to ECL-Western blotting. Immunoreactive proMMP-3 and 
TIMP-1 were detected as described in section 2. 
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both the increased steady-state levels of their mRNAs as well 
as translational ugmentation. 
To further investigate the possible translational enhance- 
ment that was observed at an earlier time point after EGF 
treatment, we treated the cells first with actinomycin D for 1- 
4 h and then with hEGF (100 ng/ml) in the presence of acti- 
nomycin D for 1 h, and examined the changes in levels of 
proMMP-3 and TIMP-1 proteins in paralleled with their 
mRNAs. As shown in Fig. 4A, pretreatment of the cells 
with actinomycin D (1 ktM) did not alter the hEGF-mediated 
production of proMMP-3 (2-3-fold) and TIMP-1 (4-5-fold). 
Furthermore, hEGF did not modulate the steady-state l vels 
of proMMP-3 and TIMP-1 mRNAs either in the presence or 
the absence of actinomycin D at the concentration of 1 pM 
(Fig. 4B). The mRNA levels of both proMMP-3 and TIMP-1 
in the control and the actinomycin D-treated cell were almost 
constant during the total 5-h treatment. On the other hand, 
RNA synthesis of the control and the hEGF-treated cells was 
completely inhibited by actinomycin D (Fig. 5). No significant 
decrease of the steady-state levels of proMMP-3 and TIMP-1 
mRNAs during a 5-h actinomycin D treatment is supported 
by relatively long half-lives of their mRNAs (16-60 h for 
proMMP-3 and >60 h for TIMP-1) [24,25]. These results 
further support he notion that the enhanced production of 
proMMP-3 and TIMP-1 during the first 1-h treatment with 
EGF is independent of transcriptional ctivity. The increased 
production of proMMP-3 and TIMP-1 is also unlikely to be 
due to the stimulation of the secretion of these proteins ince 
both proteins do not accumulate intracellularly [20,26]. 
Delany and Brinckerhoff [24] reported that the EGF- 
mediated enhanced production of proMMPs-1 and -3 in hu- 
man foreskin fibroblasts i in part regulated posttranscription- 
ally; i.e. EGF stabilizes the proMMP mRNAs, which in turn 
augments the synthesis of these proteins when measured after 
a 12-h treatment. Our present studies, however, demonstrated 
that the steady-state levels of proMMP-3 and TIMP-1 
mRNAs did not change at least during the first 1-h treatment 
with hEGF with and without actinomycin D treatment, indi- 
cating that the mRNA stabilization effect was not observed 
hEGF 
(100ng/ml) 
P roMMP-3  T IMP-1  #-act in  
(-fold) (-fold) 
Oh 1.0 1.0 
lh  1.0 1.0 
2h 1.0 1.0 
4h 1.0 1.0 
6h 1.6 1.4 
!!i i! iii iiii !ii iiii i i  i if!ill ii i 
8h 1.9 1.5 
1211 1.7 1.6 
_24h 1.9 1.7 
Fig. 2. Effects of EGF on the steady-state levels of proMMP-3 and 
TIMP-1 mRNAs in human uterine cervical fibroblasts. Confluent 
uterine cervical fibroblasts at the 10th passage in 100-mm diameter 
dishes were treated as in Fig. 1. At the time indicated, the total 
RNA was extracted and 5 ktg of the total RNA was applied to a 
nylon membrane using a slot blot apparatus as described in section 
2. The relative mRNA levels were determined by scanning of the 
radioactivity of each band with Bio-imaging analyzer BAS 2000 and 
standardizing them by 13-actin. The value of the control cells was 
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Fig. 3. Time-dependent i crease of proMMP-3 and TIMP-1 proteins 
and their mRNAs. Time-dependent i crease in the relative amounts 
of proMMP-3 protein (panel A) and TIMP-1 protein (panel C) and 
that of the corresponding mRNA levels (panels B and D) obtained 
from Figs. 1 and 2 were plotted. ProMMP-3 and TIMP-1 were not 
detected in the control cells at a 1-h time point by the method used. 
Thus, the relative protein levels were calculated as an fold-increase 
taking the 2-h time point of the control cells as 1. The relative 
mRNA levels were standardized by [3-actin taking the value of the 
control cells as 1. 
during a short period of EGF treatment. Thus, we conclude 
that the increase in proMMP-3 and TIMP-1 production at the 
earlier phase of EGF treatment most likely results from the 
enhanced translation of their messages. Similar enhanced 
translational effects of EGF were also observed with human 
dermal fibroblasts (data not shown). 
We also found that IL-lct similarly augmented the produc- 
tion of proMMP-3 and TIMP-1 without changing their 
mRNA levels in human uterine cervical cells (T. Hosono, A. 
Ito and Y. Mori, unpubl, results). When the inductive ffects 
of hEGF and IL-lc~ were compared at the same molar con- 
centration, the rate of augmentation of proMMP-3 and 
TIMP-1 by hEGF was twice as fast as that by IL-lct. There- 
fore, the translational ctivation of proMMP-3 and TIMP-1 
mRNAs appears to be a common phenomenon for these two 
factors, but EGF is more effective than IL-lct. 
It is not clear how EGF accelerates the translation of 
proMMP-3 and TIMP-1 mRNAs in human uterine cervical 
and dermal fibroblasts. The translational rate of some 
mRNAs is controlled by the phosphorylation f various cel- 
lular proteins, especially eukaryotic initiation factor-4F (eIF- 
4F) and ribosomal $6 protein [27]. These eIF-4F and riboso- 
mal $6 proteins are phosphorylated by protein kinase C 
(PKC) and $6 kinase in rabbit reticurocytes and mouse 
3T3-L1 cells, respectively, and they closely participate in the 
translation of mRNAs for protein synthesis [28,29]. In this 
point of view, it is of interest that EGF activates PKC 
[11,30] and $6 kinase [31]. Thus, it is tempting to speculate 
that EGF may accelerate the translation of proMMP-3 and 
TIMP-1 by in part activating these kinases. Indeed, we ob- 
served that a protein kinase inhibitor, 1-(5-isoquinolinesulfo- 
nyl)-2-methylpiperazine dihydrochloride (H7) diminished the 
enhanced production of proMMP-3 and TIMP-I induced by 
a 2-h treatment with hEGF (T. Hosono, A. Ito and Y. Mori, 
unpubl, results). 
In conclusion, we have demonstrated that the apparent 
augmentation of production of proMMP-3 and TIMP-1 in 
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Fig. 4. Effects of actinomycin D on the production of proMMP-3 
and TIMP-1 and on the steady-state l vels of their mRNAs in hu- 
man uterine cervical fibroblasts during the early EGF treatment. 
Confluent uterine cervical fibroblasts at the 8th passage in 100-ram 
diameter dishes were first treated with actinomycin D (1 taM) for 
the indicated periods and then cotreated with hEGF and actinomy- 
cin D for 1 h. The amounts of proMMP-3 and TIMP-1 in the cul- 
ture media were analyzed by ECL-Western blotting, and their 
mRNAs in 30 ~tg of the total RNA were monitored by Northern 
blotting as described in section 2. Panel A; protein levels of 
proMMP-3 and TIMP-1 and panel B; their mRNA levels. Lane 1, 
control cells; lane 2, cells treated with hEGF (100 ng/ml); lane 3, 
control cells pretreated with actinomycin D (1 pM) at indicated per- 
iods and then additional 1 h; and lane 4, cells pretreated with acti- 
nomycin D as lane 3 and then cotreated with hEGF (100 ng/ml) 
and actinomycin D (1 ~tM) for 1 h. 
400 
~t. 
~' 300 - o 
c -  
o 200-  
o 
~" 100  - o o 
.E_ 
El 





(O) Control  
(• )  hEGF 
* O* * 0 
I I I I 
None 1 2 3 (h) 
I I 
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Fig. 5. Effect of actinomycin D on the synthesis of total RNA in 
human uterine cervical fibroblasts during the early EGF treatment. 
Confluent uterine cervical fibroblasts at the 8th passage in 12-well 
plates were first treated with actinomycin D (1 /aM) for the indi- 
cated periods (1-3 h), and then cotreated with hEGF (100 ng/ml) 
and actinomycin D (1 I.tM) in 0.2% (w/v) LAH/MEM containing 
[5-ZH]uridine (37 kBq/ml) for 1 h. The synthesis of total RNA was 
measured as described in section 2. Each point represents the 
mean + S.D. from three individual wells. *Significantly different from 
the cells without treatment of actinomycin D (P<0.001). 
human uterine cervical cells by EGF is finely controlled via 
two different mechanisms. One is a well-recognized transcrip- 
tional mechanism by which EGF increases the steady-state 
levels of their mRNAs.  The other mechanism lies on the en- 
hancement of the translational rate of proMMP-3  and T IMP-  
1 mRNAs.  The latter mechanism may in part explain rela- 
tively higher product ion rate of these proteins compared with 
a limited increases in their mRNAs.  
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